APILIMOD
Common Variable Immunodeficiency
National Institute of Allergy and Infectious Diseases (NIAID)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Common Variable Immunodeficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Conestat Alfa IMMUNOe Research Centers | Phase 4 | BB |
Thiotepa University of Florida | Phase 2 | BB |
HUMAN IMMUNOGLOBULINS Grifols Therapeutics LLC | Phase 3 | B |
Anti-Thymoglobulin, Rabbit Paul Szabolcs | Phase 2 | CCC |
Evomela Paul Szabolcs | Phase 2 | CCC |
View all 19 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →